Parshva Agency - Cancer, TB & Tumour Drugs

Enzalutamide is an oral androgen receptor inhibitor used in the treatment of prostate cancer. It works by blocking androgen receptors, preventing the growth of cancer cells driven by male hormones. It is indicated for metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic hormone-sensitive prostate cancer (mHSPC). Enzalutamide helps delay disease progression and improves survival in patients with advanced prostate cancer.

Leuprolide acetate is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques

Denosumab is a human monoclonal antibody that inhibits RANK ligand (RANKL), a key regulator of osteoclast activity, thereby reducing bone resorption and increasing bone density. It is used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of giant cell tumor of bone. It is marketed under brand names like Prolia (for osteoporosis) and Xgeva (for oncology-related indications).

Cabazirix 60 mg Injection contains cabazitaxel, a microtubule inhibitor used in combination with prednisone to treat metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with a docetaxel-containing regimen. Cabazitaxel works by binding to tubulin, promoting its assembly into microtubules while inhibiting their disassembly, leading to stabilization of microtubules and inhibition of mitotic and interphase cellular functions, thereby preventing cancer cell division and growth.